Literature DB >> 30345050

Prognostic factors of hepatectomy in initially unresectable colorectal liver metastasis: Indication for conversion therapy.

Hiroya Iida1,2, Masaki Kaibori2, Hiroshi Wada3, Fumitoshi Hirokawa4, Takuya Nakai5, Masahiko Kinoshita6, Michihiro Hayashi4, Hidetoshi Eguchi3, Shoji Kubo6.   

Abstract

The aim of the present study was to retrospectively identify prognostic factors for long-term cumulative survival following liver resection in patients with primarily unresectable colorectal cancer who had previously received conversion therapy. A multicentre study was designed to ascertain the appropriate indication for conversion therapy. The study included 34 patients who underwent conversion therapy at 5 university hospitals. Patients' background, operative factors, recurrence rate and survival rate were evaluated, and factors influencing therapy outcomes were identified. The median duration of preoperative chemotherapy was 3 months and the response rate was 39.8%. Upon resection, the median tumour size was 47 mm and the median number of tumours was 4. The recurrence-free and cumulative survival rates 5 years after liver resection were 13.7 and 39.3%, respectively. Postoperative complications developed in 12 patients. A response rate >40% was indicated with regards to the assessed prognostic factors for long-term cumulative survival following liver resection and an absence of postoperative complications was noted. It was revealed that conversion therapy should be considered prior to liver resection, particularly for patients with response rates exceeding 40%. Absence of postoperative complications is also an independent predictor of long-term cumulative survival after liver resection. In light of these findings, it was consisted that an optimal response rate >40% could be used as an indicator for surgical resection in conversion therapy. In addition, meticulous intra- and postoperative managements are important for decreasing postoperative complications and improving long-term cumulative survival.

Entities:  

Keywords:  conversion therapy; hepatectomy; liver metastasis

Year:  2018        PMID: 30345050      PMCID: PMC6174424          DOI: 10.3892/mco.2018.1707

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  36 in total

1.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

2.  Prognostic value of Ki-67 expression in conversion therapy for colorectal liver-limited metastases.

Authors:  Hiromitsu Hayashi; Toru Beppu; Yasuo Sakamoto; Yuji Miyamoto; Naomi Yokoyama; Takaaki Higashi; Hidetoshi Nitta; Daisuke Hashimoto; Akira Chikamoto; Hideo Baba
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.

Authors:  Takao Takahashi; Yoshihisa Shibata; Yuichiro Tojima; Kenji Tsuboi; Eiji Sakamoto; Katsuyuki Kunieda; Hiroshi Matsuoka; Kazuyoshi Suzumura; Mikinori Sato; Tatsushi Naganuma; Junichi Sakamoto; Satoshi Morita; Ken Kondo
Journal:  Int J Clin Oncol       Date:  2012-03-02       Impact factor: 3.402

4.  A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.

Authors:  Marc Ychou; Michel Rivoire; Simon Thezenas; François Quenet; Jean-Robert Delpero; Christine Rebischung; Christian Letoublon; Rosine Guimbaud; Eric Francois; Michel Ducreux; Françoise Desseigne; Jean-Michel Fabre; Eric Assenat
Journal:  Ann Surg Oncol       Date:  2013-08-17       Impact factor: 5.344

5.  Prognostic significance of postoperative complications after hepatectomy for hepatocellular carcinoma.

Authors:  Yukiyasu Okamura; Shin Takeda; Tsutomu Fujii; Hiroyuki Sugimoto; Shuji Nomoto; Akimasa Nakao
Journal:  J Surg Oncol       Date:  2011-06-28       Impact factor: 3.454

6.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

7.  Poor prognosis in esophageal cancer patients with postoperative complications.

Authors:  T Hirai; Y Yamashita; H Mukaida; M Kuwahara; H Inoue; T Toge
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

8.  Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.

Authors:  Nancy E Kemeny; Fidel D Huitzil Melendez; Marinela Capanu; Philip B Paty; Yuman Fong; Lawrence H Schwartz; William R Jarnagin; Dina Patel; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

9.  Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

Authors:  T Gruenberger; J Bridgewater; I Chau; P García Alfonso; M Rivoire; S Mudan; S Lasserre; F Hermann; D Waterkamp; R Adam
Journal:  Ann Oncol       Date:  2014-12-23       Impact factor: 32.976

10.  Surgical options for initially unresectable colorectal liver metastases.

Authors:  Irinel Popescu; Sorin Tiberiu Alexandrescu
Journal:  HPB Surg       Date:  2012-10-03
View more
  1 in total

1.  Prognostic impact of conversion hepatectomy for initially unresectable colorectal liver metastasis.

Authors:  Yasuyuki Takamizawa; Manabu Inoue; Konosuke Moritani; Shunsuke Tsukamoto; Minoru Esaki; Kazuaki Shimada; Yukihide Kanemitsu
Journal:  Langenbecks Arch Surg       Date:  2022-09-07       Impact factor: 2.895

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.